Singer Andrew E. has made a significant disclosure regarding his stock option transaction involving Kyntra Bio, Inc. This transaction is noteworthy as it involves 14,000 shares of common stock, reflecting ongoing engagement in the pharmaceutical preparations sector.
Background
Singer Andrew E. is associated with Kyntra Bio, Inc., a company that operates under the SIC classification of Pharmaceutical Preparations. The company's CIK is 0000921299, and it is publicly traded under the symbol KYNB. Kyntra Bio is known for its innovative contributions to the life sciences field.
What the Filing Says
According to the recent filing dated October 6, 2026, Singer reported a stock option transaction dated October 1, 2026. The filing states, "The shares subject to the option shall vest in twelve equal quarterly installments measured from the date of grant." The exercise price for the stock option is set at $6.50 per share.
Impact
This transaction may affect Kyntra Bio's stock performance and investor sentiment, particularly as it showcases the company's commitment to incentivizing its executives and aligning their interests with shareholders. Additionally, it may draw attention from other companies in the pharmaceutical preparations industry, as they evaluate their own compensation and incentive strategies.
What's Next
The filing does not say what happens next.